Perspective Therapeutics (CATX) News Today $3.17 -0.05 (-1.55%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$3.26 +0.10 (+3.00%) As of 06/13/2025 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CATX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Cantor Fitzgerald Predicts CATX FY2026 EarningsJune 12 at 3:03 AM | americanbankingnews.comLifeSci Capital Sticks to Their Buy Rating for Perspective Therapeutics (CATX)June 10, 2025 | theglobeandmail.comPerspective Therapeutics Inc. (AAJ0.SG)June 10, 2025 | finance.yahoo.comCantor Fitzgerald Weighs in on CATX FY2026 EarningsPerspective Therapeutics, Inc. (NYSE:CATX - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2026 EPS estimates for Perspective Therapeutics in a research report issued to clients and investors on Monday, June 9th. Cantor Fitzgerald analyst L. Watsek anticipates that the coJune 10, 2025 | marketbeat.comAmeriprise Financial Inc. Sells 645,170 Shares of Perspective Therapeutics, Inc. (NYSE:CATX)Ameriprise Financial Inc. cut its stake in shares of Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) by 97.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 17,326 shares of the company's stock afJune 8, 2025 | marketbeat.com151,610 Shares in Perspective Therapeutics, Inc. (NYSE:CATX) Acquired by Two Sigma Advisers LPTwo Sigma Advisers LP bought a new stake in shares of Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 151,610 shares of the company's stock, vJune 5, 2025 | marketbeat.comRoyal Bank of Canada Upgrades Perspective Therapeutics (NYSE:CATX) to Moderate BuyJune 5, 2025 | americanbankingnews.comPerspective Therapeutics (CATX) Gets a Buy from ScotiabankJune 5, 2025 | theglobeandmail.comSquarepoint Ops LLC Purchases Shares of 196,208 Perspective Therapeutics, Inc. (NYSE:CATX)Squarepoint Ops LLC purchased a new stake in shares of Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 196,208 shares of the company's stock, valued atJune 4, 2025 | marketbeat.comPerspective Therapeutics price target raised to $16 from $15 at RBC CapitalJune 3, 2025 | msn.comRoyal Bank of Canada Forecasts Strong Price Appreciation for Perspective Therapeutics (NYSE:CATX) StockRoyal Bank of Canada boosted their price target on Perspective Therapeutics from $15.00 to $16.00 and gave the company an "outperform" rating in a research note on Tuesday.June 3, 2025 | marketbeat.comPerspective Therapeutics, Inc. (NYSE:CATX) Shares Sold by Nuveen Asset Management LLCNuveen Asset Management LLC lowered its position in shares of Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) by 13.0% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 722,048 shares of the company's stock after selling 108,165 shares dJune 3, 2025 | marketbeat.comTwo Sigma Investments LP Takes $2.08 Million Position in Perspective Therapeutics, Inc. (NYSE:CATX)Two Sigma Investments LP acquired a new stake in shares of Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm acquired 650,351 shares of the company's stock, valued at approximately $2,075,000. Two Sigma InJune 2, 2025 | marketbeat.comPerspective Therapeutics Provides Updated Interim Results and Safety Findings for [212Pb]VMT-α-NET at ASCO 2025June 1, 2025 | nasdaq.comPerspective Therapeutics, Inc. (CATX) Reports Positive Results for NET Treatment TrialMay 31, 2025 | insidermonkey.comMillennium Management LLC Buys New Stake in Perspective Therapeutics, Inc. (NYSE:CATX)Millennium Management LLC bought a new stake in Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm bought 1,295,343 shares of the company's stock, valued at approximately $4,132,000. Millennium Management LLMay 31, 2025 | marketbeat.comPerspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual MeetingMay 30, 2025 | globenewswire.comCATX Perspective Therapeutics, Inc.May 29, 2025 | seekingalpha.comJanus Henderson Group PLC Has $57,000 Stake in Perspective Therapeutics, Inc. (NYSE:CATX)Janus Henderson Group PLC cut its position in shares of Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) by 99.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 17,839 shares of the company's stocMay 27, 2025 | marketbeat.comPerspective Therapeutics, Inc. (NYSE:CATX) Given Consensus Rating of "Buy" by BrokeragesPerspective Therapeutics, Inc. (NYSE:CATX - Get Free Report) has earned a consensus rating of "Buy" from the eleven analysts that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation, seven have given a buy recommendation and tMay 26, 2025 | marketbeat.comHC Wainwright Has Pessimistic Outlook of CATX Q3 EarningsPerspective Therapeutics, Inc. (NYSE:CATX - Free Report) - Equities research analysts at HC Wainwright lowered their Q3 2025 earnings per share estimates for Perspective Therapeutics in a research note issued to investors on Monday, May 19th. HC Wainwright analyst R. Burns now forecasts that theMay 23, 2025 | marketbeat.comQ1 Earnings Forecast for CATX Issued By HC WainwrightPerspective Therapeutics, Inc. (NYSE:CATX - Free Report) - Research analysts at HC Wainwright issued their Q1 2026 EPS estimates for shares of Perspective Therapeutics in a report issued on Monday, May 19th. HC Wainwright analyst R. Burns forecasts that the company will post earnings of ($0.32) pMay 22, 2025 | marketbeat.comPerspective Therapeutics’ SWOT analysis: rare disease stock faces clinical hurdlesMay 21, 2025 | investing.comPerspective Therapeutics, Inc. (CATX): Analysts See 460% Upside PotentialMay 21, 2025 | insidermonkey.comVelan Capital Investment Management LP Purchases New Stake in Perspective Therapeutics, Inc. (NYSE:CATX)Velan Capital Investment Management LP acquired a new position in shares of Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 500,000 shares of tMay 21, 2025 | marketbeat.comBalyasny Asset Management L.P. Invests $418,000 in Perspective Therapeutics, Inc. (NYSE:CATX)Balyasny Asset Management L.P. purchased a new stake in shares of Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 130,914 shares of the company's stock, vaMay 19, 2025 | marketbeat.comSphera Funds Management LTD. Lowers Holdings in Perspective Therapeutics, Inc. (NYSE:CATX)Sphera Funds Management LTD. trimmed its holdings in Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) by 21.9% in the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 460,247 shares of the company's stock after selling 129,048 shares during thMay 18, 2025 | marketbeat.comCubist Systematic Strategies LLC Invests $834,000 in Perspective Therapeutics, Inc. (NYSE:CATX)Cubist Systematic Strategies LLC bought a new position in shares of Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 261,474 shares of the companMay 17, 2025 | marketbeat.comTruist Financial Keeps Their Buy Rating on Perspective Therapeutics (CATX)May 16, 2025 | theglobeandmail.comOctagon Capital Advisors LP Grows Stock Position in Perspective Therapeutics, Inc. (NYSE:CATX)Octagon Capital Advisors LP grew its position in shares of Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) by 62.1% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,304,752 shares of the company's stock afterMay 15, 2025 | marketbeat.comPerspective Therapeutics, Inc.: Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 ResultsMay 14, 2025 | finanznachrichten.deSchonfeld Strategic Advisors LLC Sells 423,123 Shares of Perspective Therapeutics, Inc. (NYSE:CATX)Schonfeld Strategic Advisors LLC reduced its holdings in shares of Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) by 71.5% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 168,500 shares of the company's stock after selling 423,123 shares during theMay 13, 2025 | marketbeat.comPerspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 ResultsMay 12, 2025 | globenewswire.comPerspective Therapeutics, Inc. (NYSE:CATX) Shares Bought by Deerfield Management Company L.P. Series CDeerfield Management Company L.P. Series C boosted its stake in shares of Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) by 4.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,938,May 10, 2025 | marketbeat.comJPMorgan Chase & Co. Boosts Stock Position in Perspective Therapeutics, Inc. (NYSE:CATX)JPMorgan Chase & Co. raised its position in shares of Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) by 498.3% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 149,045 shares of the company's stock after buying an additional 124,133 sMay 3, 2025 | marketbeat.comPerspective Therapeutics to Participate in Upcoming May Investor ConferencesMay 1, 2025 | globenewswire.comPerspective Therapeutics, Inc. (NYSE:CATX) Given Average Recommendation of "Buy" by BrokeragesShares of Perspective Therapeutics, Inc. (NYSE:CATX - Get Free Report) have been assigned an average recommendation of "Buy" from the eleven analysts that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a hold rating, seven have given a buy rating and three havApril 30, 2025 | marketbeat.comPerspective Therapeutics Announces First Patient Dosed with PSV359 in a Phase 1/2a Study in Patients with FAP-α Positive Solid TumorsApril 29, 2025 | finance.yahoo.comPerspective Therapeutics, Inc. (NYSE:CATX) Shares Sold by Marshall Wace LLPMarshall Wace LLP lessened its stake in shares of Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) by 45.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 807,172 shares of the company's stock after selling 683,619 shares durinApril 29, 2025 | marketbeat.com215,725 Shares in Perspective Therapeutics, Inc. (NYSE:CATX) Bought by Jump Financial LLCJump Financial LLC bought a new stake in Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 215,725 shares of the company's stock, valued at approximatelyApril 25, 2025 | marketbeat.comTruist Financial Sticks to Their Buy Rating for Perspective Therapeutics (CATX)April 23, 2025 | markets.businessinsider.comPerspective Therapeutics Announces Acceptance of VMT-α-NET and VMT01 Data for Presentation at the 2025 ASCO Annual MeetingApril 23, 2025 | globenewswire.comWalleye Capital LLC Purchases 457,675 Shares of Perspective Therapeutics, Inc. (NYSE:CATX)Walleye Capital LLC boosted its position in Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) by 2,526.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 475,792 shares of the compaApril 22, 2025 | marketbeat.comPerspective Therapeutics, Inc. (NYSE:CATX) Shares Sold by Altium Capital Management LLCAltium Capital Management LLC decreased its position in shares of Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) by 68.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 92,224 shApril 20, 2025 | marketbeat.comAffinity Asset Advisors LLC Acquires 800,000 Shares of Perspective Therapeutics, Inc. (NYSE:CATX)Affinity Asset Advisors LLC raised its holdings in Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) by 160.0% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,300,000 shares of the cApril 17, 2025 | marketbeat.comPerspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial ResultsApril 17, 2025 | globenewswire.comPerspective announces first patient dosed in Phase 1/2a trial of 212PbVMT01April 11, 2025 | markets.businessinsider.comPerspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 Monotherapy at 1.5 mCi in a Phase 1/2a Study of MC1R-Positive Metastatic MelanomaApril 11, 2025 | globenewswire.comIs Now The Time To Invest In Perspective TherapeuticsApril 9, 2025 | seekingalpha.comTruist Financial Reaffirms Their Buy Rating on Perspective Therapeutics (CATX)April 9, 2025 | markets.businessinsider.com Get Perspective Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CATX and its competitors with MarketBeat's FREE daily newsletter. Email Address CATX Media Mentions By Week CATX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CATX News Sentiment▼0.910.89▲Average Medical News Sentiment CATX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CATX Articles This Week▼74▲CATX Articles Average Week Get Perspective Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CATX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MDXG News INMD News BBNX News SIBN News IRMD News CBLL News RXST News BFLY News AVNS News EMBC News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:CATX) was last updated on 6/15/2025 by MarketBeat.com Staff From Our PartnersAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Perspective Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Perspective Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CATX Stock Free CATX Stock Alerts